Oncostrata joins Kadans Science Partner’s London Innovation Centre in Canary Wharf
17 December 2025: Kadans Science Partner (“Kadans”) has today announced that Oncostrata, an oncology and haematology clinical development company, is joining the London Innovation Centre at 20 Water Street, Canary Wharf and the Kadans European Community.
Oncostrata is a UK-based company working with global biotech and pharmaceutical clients to provide expert guidance across the full lifecycle of clinical development, from clinical trial design and scientific oversight to regulatory documentation and health-authority submissions.
The move is part of the next phase of growth for Oncostrata, driven by the desire to have a London presence in a well-connected and dynamic environment with access to a community of innovators across oncology and broader therapeutic areas.
Based in the heart of Canary Wharf’s growing life sciences and healthcare community, the London Innovation Centre hosts a thriving collective of forward-thinking businesses who are united by a commitment to collaboration and innovation.
As part of the London Innovation Centre and Kadans’ wider network, Oncostrata will gain valuable access to a likeminded community of over 500 tenants across the UK and Europe. This presents a unique opportunity for the Company to contribute to the ecosystem by sharing its expertise, while fostering new collaborations with other oncology-focused companies to accelerate the development of novel cancer therapies.
The London Innovation Centre is a state-of-the-art facility comprising 40,000 sq ft of laboratory space, flexible CL2 wet labs and bespoke offices and meeting rooms. Oncostrata joins a growing community of businesses and innovators based in Canary Wharf, including Myricx Bio, AviadoBio and others who benefit from the unique offering the Centre provides. This includes access to shared equipment, resources and support to help them achieve their goals, such as tailored, hands-on support in areas such as business development, access to regular business and technical knowledge sharing events, and a global portfolio of specialised scientific equipment.
Joanna Hanks, Founder and Head of Clinical Science, Oncostrata, commented: “We are very excited to be a part of the London Innovation Centre. The energy and enthusiasm is evident and ideas flow freely, being embedded within a wider network of world leading labs and university hospitals is also incredibly inspiring. We’ve already begun engaging with teams who share our commitment to oncology innovation, and an enthusiasm to advance preclinical ideas into the clinical stage. A clear pathway to first-in-humans clinical trials is where we can help early biotechs and we’re excited about the possibilities these initial conversations are unlocking.”
Katie Nelson, Head of Leasing UK & Ireland, Kadans Science Partner, said: “Oncostrata’s presence at the London Innovation Centre at Canary Wharf strengthens Kadans’ growing pan-European life sciences network. The company’s expertise in Oncology Clinical Development will further enhance the Centre’s mission to support early-stage innovators by providing access to the resources, infrastructure and collaborative environment needed to bring new ideas to fruition and accelerate progress.”
The London Innovation Centre forms part of the broader life science offering at Canary Wharf, which, once complete in Q1 2028, will also include One North Quay. Spread across 23 storeys, the 823,000 sq ft GIA commercial vertical health and life sciences campus is set to be the tallest and most technically sophisticated purpose-built commercial laboratory building in the world.
